MARKET

XNCR

XNCR

Xencor
NASDAQ
19.53
+0.09
+0.44%
Opening 14:01 06/20 EDT
OPEN
19.23
PREV CLOSE
19.44
HIGH
19.59
LOW
18.98
VOLUME
209.83K
TURNOVER
0
52 WEEK HIGH
27.37
52 WEEK LOW
16.49
MARKET CAP
1.20B
P/E (TTM)
-8.9045
1D
5D
1M
3M
1Y
5Y
Relative Strength Alert For Xencor
NASDAQ · 3d ago
Weekly Report: what happened at XNCR last week (0610-0614)?
Weekly Report · 3d ago
Peeling Back The Layers: Exploring Xencor Through Analyst Insights
Xencor (NASDAQ:XNCR) is a clinical-stage biopharmaceutical company. The company is developing antibodies to treat severe and life-threatening diseases. 5 analysts provided ratings for Xencor in the latest quarter. Xencor has an average price target of $35.4 and 12-month price targets of $31.00.
Benzinga · 6d ago
Xencor Is Maintained at Strong Buy by Raymond James
Dow Jones · 6d ago
Xencor Price Target Cut to $40.00/Share From $58.00 by Raymond James
Dow Jones · 6d ago
Raymond James Maintains Strong Buy on Xencor, Lowers Price Target to $40
Benzinga · 6d ago
Xencor Price Target Cut to $32.00/Share From $34.00 by BMO Capital
Dow Jones · 6d ago
Xencor Is Maintained at Outperform by BMO Capital
Dow Jones · 6d ago
More
About XNCR
Xencor, Inc. is a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and other serious diseases. More than 20 candidates engineered with its XmAb technology are in clinical development, and three XmAb medicines are marketed by partners. Its XmAb engineering technology enables small changes to a protein structure that result in new mechanisms of therapeutic action. Its wholly owned development candidates include Vudalimab, XmAb819, XmAb808, and XmAb541. Candidates co-developed with partners include Plamotamab. Candidates advanced by partners include Xaluritamig (AMG 509), ASP2138, JNJ-9401, JNJ-1493, and Novartis XmAb undisclosed antibody candidate. Its cytokine drug candidates in clinical development consist of fbalropendekin alfa (XmAb306/RG6323), XmAb564, and XmAb662. Its other clinical-stage drug candidates consist of Obexelimab, AIMab7195 (XmAb7195), and Xpro1595. Vudalimab is a bispecific antibody that targets PD-1 and CTLA-4.

Webull offers Xencor Inc stock information, including NASDAQ: XNCR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, XNCR stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading XNCR stock methods without spending real money on the virtual paper trading platform.